Prevention of transthyretin amyloid disease by changing protein misfolding energetics

Per Hammarström1, R Luke Wiseman, Evan T Powers

  • 1Department of Chemistry and The Skaggs Institute of Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.

Science (New York, N.Y.)
|February 1, 2003
PubMed

Insights

Small molecules can treat amyloid diseases by stabilizing the native protein state, preventing harmful amyloid fibril formation. This kinetic stabilization strategy is effective for transthyretin amyloidosis and potentially other amyloid diseases.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Amyloid diseases are linked to the formation of amyloid fibrils.
  • Current amyloid inhibitors shift aggregation equilibrium away from the amyloid state.
  • Genetic evidence suggests small molecule inhibition of amyloid fibril formation is a viable therapeutic strategy.

Purpose of the Study:

  • To describe novel transthyretin amyloidosis inhibitors.
  • To investigate the mechanism of action for these inhibitors.
  • To explore the potential of kinetic stabilization as a therapeutic strategy for amyloid diseases.

Main Methods:

  • Synthesis and characterization of small molecule inhibitors.
  • Assays to measure protein misfolding and amyloid formation.
  • Analysis of a known trans-suppressor mutation (T119M) in transthyretin.

Main Results:

  • Developed small molecules that inhibit transthyretin amyloidosis.
  • These inhibitors increase the kinetic barrier of protein misfolding.
  • Stabilization of the native protein state prevents amyloidogenesis.
  • The T119M mutation functions via kinetic stabilization, similar to the small molecules.

Conclusions:

  • Small molecules can prevent amyloid diseases by kinetically stabilizing the native protein state.
  • This strategy offers a new approach for treating transthyretin amyloidosis.
  • Kinetic stabilization is a promising therapeutic avenue for various amyloid diseases.

Related Concept Videos

Protein Folding01:22

Protein Folding

Overview
Protein Folding01:22

Protein Folding

Overview
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Protein Folding Quality Check in the RER01:29

Protein Folding Quality Check in the RER

ER is the primary site for the maturation and folding of soluble and transmembrane secretory proteins. The calnexin cycle is a specific chaperone system that folds and assesses the confirmation of N-glycosylated proteins before they can exit the ER lumen. The primary players of this quality check pipeline are the lectins, ER-resident chaperones, and a glucosyl transferase enzyme. In case the calnexin system in the lumen fails to salvage a misfolded protein, it is transported to the cytoplasm...
Protein Folding01:25

Protein Folding

Proteins are chains of amino acids linked together by peptide bonds. Upon synthesis, a protein folds into a three-dimensional conformation, critical to its biological function. Interactions between its constituent amino acids guide protein folding, and hence the protein structure is primarily dependent on its amino acid sequence.
Protein Structure Is Critical to Its Biological Function
Proteins perform a wide range of biological functions such as catalyzing chemical reactions, providing...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...